Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast
Objective. Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases that primarily affect striated muscles; skin, joints, and lungs may be involved with different degrees of severity. Traditional treatment relies on high-dose glucocorticoids and conventional synthetic disease-modifying...
Main Authors: | Chiara Rizzo, Silvia Grazzini, Edoardo Conticini, Hector Chinoy, Roberto D’Alessandro, Federica Camarda, Luca Cantarini, Bruno Frediani, Giuliana Guggino, Lidia La Barbera |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2025-01-01
|
Series: | Reumatismo |
Subjects: | |
Online Access: | https://www.reumatismo.org/reuma/article/view/1718 |
Similar Items
-
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
by: Ennio Giulio Favalli, et al.
Published: (2023-08-01) -
Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients
by: Simone Parisi, et al.
Published: (2024-01-01) -
Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound
by: Giacomo Cozzi, et al.
Published: (2024-12-01) -
The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: A systematic review and meta-analysis
by: Athanasios Vassilopoulos, et al.
Published: (2022-10-01) -
Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
by: Ennio Lubrano, et al.
Published: (2022-12-01)